RxDoctor Payments DataLook up a doctor →

Cassie Port

Nurse Practitioner · West Jordan, UTNPI 1912671272

Payments from drug & device makers

$9,389in general payments, 2019–2025

Across 446 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • AstraZeneca$1K
  • GSK$728
  • Harmony Biosciences LLC$714
  • Mylan Specialty L.p.$557
  • Insmed, Inc.$474
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$1502%
  • Travel & lodging$3464%
  • Food & beverage$8,65192%
  • Education$2423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,389 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$81,226
Medicare patients
483
Services billed
871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter142$116,401
Stiolto RespimatTiotropium Br/Olodaterol Hcl166$104,789
Spiriva RespimatTiotropium Bromide136$103,389
Breztri AerosphereBudesonide/Glycopyr/Formoterol99$81,847
Orenitram ErTreprostinil Diolamine13$61,192
Ambrisentan15$42,558
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr59$38,172
SymbicortBudesonide/Formoterol Fumarate107$35,377
Tadalafil16$24,950
Fluticasone-SalmeterolFluticasone Propion/Salmeterol130$21,101
Breo ElliptaFluticasone/Vilanterol35$19,602
Albuterol Sulfate HfaAlbuterol Sulfate427$12,308
Advair HfaFluticasone Propion/Salmeterol24$11,774
Combivent RespimatIpratropium/Albuterol Sulfate13$10,757
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate42$9,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$427$218,935315 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$728$174,175236 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,055$117,224206 claims
MerckDulera$47$8,75616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in West Jordan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →